BIOMAT Database Logo BIOMAT Database Logo

Relative unresponsiveness of obese diabetic compared to obese non-diabetic subjects to the weight-reducing effect of fenfluramine. 1977

M A Otim

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D003920 Diabetes Mellitus A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
D005260 Female Females
D005277 Fenfluramine A centrally active drug that apparently both blocks serotonin uptake and provokes transport-mediated serotonin release. Fintepla,Fenfluramine Hydrochloride,Fenfluramine Hydrochloride, (+-)-Isomer,Fenfluramine Hydrochloride, R-Isomer,Fenfluramine, (+-)-Isomer,Fenfluramine, R-Isomer,Isomeride,Pondimin,Fenfluramine Hydrochloride, R Isomer,Fenfluramine, R Isomer,Hydrochloride, Fenfluramine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

M A Otim
Weight-reducing effect of diguanides in obese non-diabetic women.
April 1969, British medical journal,
M A Otim
Phenformin compared with fenfluramine in the treatment of obese diabetic patients.
May 1976, The Practitioner,
M A Otim
The effect of fenfluramine on obese, maturity-onset diabetic patients.
April 1979, Acta endocrinologica,
M A Otim
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
July 2013, Lipids in health and disease,
M A Otim
Understanding intestinal glucose transporter expression in obese compared to non-obese subjects.
April 2018, Surgical endoscopy,
M A Otim
Effects of fenfluramine in hypertriglyceridemic obese subjects.
January 1988, International journal of obesity,
M A Otim
Effect of fenfluramine on insulin/growth hormone ratio in obese subjects.
January 1988, Pharmacology,
M A Otim
Obese subjects have significantly higher serum prooxidantantioxidant balance values compared to normal-weight subjects.
January 2013, Clinical laboratory,
M A Otim
Does Glycated Albumin Increase with Body Weight Reduction in Obese Non-Diabetic Subjects?
September 2019, Annals of clinical and laboratory science,
M A Otim
REDUCING obese subjects.
August 1958, Nutrition reviews,
Copied contents to your clipboard!